Archean Sciences raises $385,000 for living-neuron computers

Why it matters

The SAFE financing gives two UIUC researchers capital to move biological computing from academic systems into commercial drug discovery and AI, where validation and laboratory costs rise quickly.

Austin Ellis-Mohr and Mattia Gazzola have sold $385,000 in SAFEs for Archean Sciences, financing their attempt to turn living human neurons into a platform for neurological drug research and computing.

The Form D filed with the SEC on August 13 reports an indefinite offering amount. Archean made the first sale on May 27, meaning the financing had been underway for roughly 11 weeks before the notice became public. The filing does not identify a lead, the valuation or the SAFE terms.

Archean is a new Delaware corporation based in Champaign, Illinois, and the filing marks it as having no revenue.

The founders are moving years of university research toward a commercial operation. Ellis-Mohr recently completed a doctorate centered on the information dynamics of biological and artificial intelligence. His 2024 work includes a directed-information presentation and proceedings item coauthored with Lav Varshney. He also wrote "Synthetic Neurocomputers," a 2024 U.S. Department of Energy workshop white paper, with Gazzola and Varshney. (austinellismohr.com)

Gazzola, Archean's chief scientific officer, is a University of Illinois Urbana-Champaign associate professor whose research spans bio-hybrid robotics, computing and high-performance computing. His lab contributed to an open platform for interfacing with living neurons and previously built a swimming biological robot with an onboard neuron-based processing unit. (mechse.illinois.edu)

From university research to a commercial operation

The founders had already secured early, nontraditional backing before selling the SAFEs. On April 17, Archean won the $100,000 grand prize at UIUC's Cozad New Venture Challenge, along with a $10,000 Paul Magelli Innovation Award from Illinois Ventures and $10,000 from Origin Ventures.

Ellis-Mohr said at the time that the awards would fund operations, hiring, targeted research and product development. The first SAFE sale followed on May 27. (landuyt.illinois.edu)

That sequence captures the immediate task facing Archean. Ellis-Mohr and Gazzola already have research credentials and methods for reading and stimulating neural cultures. They are raising money to package those methods into a repeatable system that pharmaceutical researchers or computing customers can use.

On its website, Archean describes an autonomous laboratory that programs living brain cells and continuously measures molecular state, cellular structure, network function and experimental outcomes. An internal intelligence system called "aris" is intended to select experiments, learn from their results and direct subsequent work. Archean says the same infrastructure could support therapeutic discovery, biological computing and neural interfaces. (archean.bio)

The validation burden

Archean's two primary markets demand different proof.

Drug developers need evidence that neuron-on-chip experiments predict outcomes better or faster than existing cellular and animal models. Archean has positioned its system for research into brain disorders including Alzheimer's and Parkinson's, but its commercial case will depend on disease-specific data, reproducibility and results tied to actual drug-development decisions.

Computing customers need benchmarks. Archean and UIUC describe living neurons as a low-energy substrate for AI workloads, drawing an intuitive comparison with the brain's efficiency. Public materials do not establish a measured energy, speed or reliability advantage over silicon for a defined workload. The SAFE financing buys time to produce that evidence; the filing itself shows Archean remains pre-revenue. (sec.gov)

The autonomous-lab component may become the bridge between Archean's therapeutic and computing ambitions. A system that can run controlled neural experiments repeatedly, collect data and modify the next experiment could generate the datasets required to train biological systems while giving drug researchers a programmable testing environment. Archean's defensibility will depend on whether that loop produces proprietary experimental data and reliable results, rather than another one-off laboratory demonstration.

Living compute is already becoming a market

Archean is entering a field where several groups have moved beyond research papers and begun selling access or equipment.

Cortical Labs' CL1, a biological-computing device, combines lab-grown neurons and silicon in a self-contained system with a bidirectional stimulation interface. FinalSpark's Neuroplatform, a remote biological-computing research service, offers access to brain organoids, real-time stimulation and a Python interface for research groups.

The capital requirements are also rising. The Biological Computing Co., previously known as Biological Black Box, announced a $25 million seed round led by Primary in February focused on applying neuron-based systems to computer vision, generative video and AI infrastructure.

Against that backdrop, Archean's $385,000 is a formation-stage financing rather than a full commercialization round. Its proposed scope is unusually broad: an experimental engine for neuroscience, a drug-discovery platform and a new computing substrate. The founders' academic work gives that plan a technical base. The next stage requires narrower proof, starting with a reproducible result that a customer will fund.

The Form D shows Ellis-Mohr and Gazzola have begun assembling capital for that transition. Their wager is that the same closed-loop system used to study living neurons can eventually teach those cells to perform useful work.